Shield Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Shield Therapeutics generated cash of -$37,126,000, which is less than the previous year. Cash used in financing activities reached the amount of $49,656,000 last year. Net change in cash is therefore $10,546,000.
Cash Flow
| 2014 | -3.34M | -92K | 2.36M |
|---|---|---|---|
| 2015 | -4.18M | -132K | 4.56M |
| 2016 | -10.25M | -2.99M | 33.50M |
| 2017 | -16.15M | -3.40M | 11.88M |
| 2018 | -178K | -3.34M | 0 |
| 2019 | -4.06M | -1.36M | -203K |
| 2020 | -1.4M | -20K | -47K |
| 2021 | -16.73M | -2.05M | 27.58M |
| 2022 | -18.24M | -1.69M | 7.70M |
| 2023 | -37.12M | -2.43M | 49.65M |
STX.L Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 3.40M | 12.11M | 2.94M | 4.14M | 9.77M | 13.29M | 20.97M | 725K | 477K | 1.55M |
Operating activities | ||||||||||
Net income | -33.29M | -40.44M | -19.33M | -2.63M | -8.8M | -1.79M | -19.58M | -15.01M | -24.48M | -13.43M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 1.07M | 2.36M | 2.20M | 2.70M | 2.62M | 2.35M | 2.43M | 1.93M | 50K | 36K |
Stock-based compensation expense | 875K | 912K | 1.33M | 1.05M | 456K | 0 | 560K | 288K | 882K | 247K |
| Deferred income tax benefit | 875K | 912K | 1.33M | 1.05M | 456K | 0 | 560K | 288K | 882K | 247K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -5.63M | -2.31M | -2.87M | -264K | 681K | 0 | -171K | 0 | -1.52M | 0 |
Inventories | -1.16M | 178K | -256K | -431K | -839K | 16K | 293K | -418K | 0 | 0 |
Accounts payable | 1.53M | 6.03M | 1.98M | -2.07M | 999K | 0 | -409K | 0 | 2.80M | 0 |
Cash generated by operating activities | -37.12M | -18.24M | -16.73M | -1.4M | -4.06M | -178K | -16.15M | -10.25M | -4.18M | -3.34M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -239K | -1.89M | -2.06M | -23K | -1.38M | -3.34M | -3.40M | -3.17M | -132K | -92K |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 177K | 0 | 0 |
Cash generated by investing activities | -2.43M | -1.69M | -2.05M | -20K | -1.36M | -3.34M | -3.40M | -2.99M | -132K | -92K |
Financing activities | ||||||||||
Common Stock Issued | 26.81M | 87K | 27.70M | 6K | 34.09K | 0 | 16.80M | 36.43M | 3.50M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | -82K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 23.99M | 9.08M | 0 | 0 | 0 | 0 | 0 | 0 | 1.06M | 0 |
Cash used in financing activities | 49.65M | 7.70M | 27.58M | -47K | -203K | 0 | 11.88M | 33.50M | 4.56M | 2.36M |
Net Change In Cash | 10.54M | -9.29M | 9.17M | -1.20M | -5.63M | -3.52M | -7.67M | 20.25M | 248K | -1.07M |
Cash at end of period | 13.94M | 2.82M | 12.11M | 2.94M | 4.14M | 9.77M | 13.29M | 20.97M | 725K | 477K |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |